Aparna Pharmaceuticals, a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Advanced Drug Intermediates, has announced two significant developments in its growth journey. The company’s manufacturing facility in Pydibhimavaram, Srikakulam, Andhra Pradesh, has received European Union Good Manufacturing Practice (EUGMP) site approval. Simultaneously, the company launched Aparna Laboratories Pvt. Ltd., a cutting-edge research and development center spread across 7,300 sq. ft. in Genome Valley, Hyderabad — India’s first organized life sciences cluster. These milestones reaffirm Aparna’s commitment to quality, compliance, and pharmaceutical innovation.
Strengthening Global Compliance with EUGMP Certification
Alongside EUGMP clearance, Aparna Pharmaceuticals secured its first Certificate of Suitability (CEP) for Clopidogrel Hydrogen Sulfate. The EUGMP approval marks a crucial step forward, enabling the company to expand into European markets with high-quality medicines.
As per the press release, the Pydibhimavaram facility had already received approval from the USFDA early last year. With additional certifications from WHO-GMP and CDSCO, the facility is now aligned with multiple global benchmarks. These recognitions reinforce Aparna’s position as a trusted partner in the global healthcare ecosystem.
Leadership Perspective
Commenting on the achievements, Mr. Rakesh Reddy, Managing Director, Aparna Pharmaceuticals, said:
“These developments mark a significant step forward as we align with the highest global benchmarks of quality and compliance. The EUGMP approval, combined with the launch of our R&D center in Genome Valley, reflects our unwavering commitment to standardization and continuous innovation. These achievements strengthen our ability to serve regulated markets, accelerate the development of complex molecules, continue R&D in areas of interest, and realize our vision of becoming a trusted partner in advancing healthcare worldwide.”
Expanding Manufacturing Capabilities
The Pydibhimavaram site spans 170,000 sq. mt. (~40 acres) and currently produces around 250 MT per month of pharmaceutical APIs and advanced intermediates across multiple therapeutic categories. With continued investments in manufacturing, R&D, and regulatory compliance, the company is targeting a 30% CAGR over the next five years. This growth will be driven by expanding product portfolios, strong demand from regulated markets, and deeper collaborations with global partners on custom manufacturing projects.
Launch of State-of-the-Art R&D Center
Aligned with its growth strategy, Aparna has established a world-class R&D center in Genome Valley. This facility aims to strengthen the company’s in-house product portfolio while positioning Aparna as a preferred Contract Development and Manufacturing Organization (CDMO) partner. By combining innovation with reliability, the center will deliver advanced solutions to leading healthcare companies worldwide.
Driving Innovation-Led Growth
With these milestones, Aparna Pharmaceuticals is well-positioned to accelerate its innovation-driven growth journey, deepen its presence in regulated global markets, and contribute meaningfully to making healthcare safer, more effective, and affordable for patients worldwide.